Phase IV Bioseal Study in Brain Tumor Surgery
The objective of this study is to observe the clinical utility and performance of Bioseal when used as an adjunct to hemostasis versus Standard of Care (SoC) in elective meningioma surgery.
Hemostasis|Meningioma Surgery
BIOLOGICAL: Bioseal Fibrin Sealant|OTHER: Standard of Care (SoC)
Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS., The percentage of participants with hemostasis at the Target Bleeding Site (TBS) at 6 minutes following start of treatment application. Hemostasis is defined as no detectable bleeding at the TBS., Intra-operative, 6 minutes following randomization
Hemostasis at the TBS at 3 Minutes Following Treatment Application, The percentage of participants with hemostasis at the Target Bleeding Site (TBS) at 3 minutes following start of treatment application. Hemostasis was defined as no detectable bleeding at the TBS., Intra-operative, 3 minutes following randomization|Incidence of Neurosurgical Complications, Central Nervous System Events and Surgical Wound Complications., Through 30-day follow-up|Incidence of Potential Bleeding-related Adverse Events, Through 30-day follow-up
The objective of this study is to observe the clinical utility and performance of Bioseal when used as an adjunct to hemostasis versus Standard of Care (SoC) in elective meningioma surgery.